HTA Whitepaper Discusses Resulting Value and Economic Benefits
In a whitepaper by researchers at the USC Schaeffer Center and Aspen Institute Advisory Panel, the authors discuss how an [...]
Cystic Fibrosis Drug Pricing Violates Human Rights According to Patients
In an unusual move, a coalition of cystic fibrosis patients and their families have filed a complaint with the United [...]
ICER and Other Stakeholders address High Cost of Rare Disease Therapy
At the AMCP Nexus 2020 Virtual meeting, two major themes emerged from the specialty pharmacy practice sessions: new methods for [...]
[Podcast] Is Fee-For-Service the Smoking Gun for U.S. Health Care Spending?
It is no secret that fee-for-service models incentivize physicians and health systems to perform more tasks than may be needed. [...]
Will more journals start charging submission fees?
COVID-19 has negatively impacted research and library budgets and reduced available funds for subscriptions and article processing charges (APCs). The downstream impacts [...]
Town Hall Meeting Sparks Thought-provoking Discussion About US Healthcare Spending
A diverse group of health care experts and stakeholders participated in the Going Below The Surface (GBTS) Forum’s first ever [...]
How Government Permits Cross-subsidies to Inflate Healthcare Costs
Government often permits companies to overcharge one set of consumers in order to subsidize other consumers in a market-distorting phenomenon [...]
Hospitals and Outpatient Care Are the Primary Drivers of Sky-high US Healthcare Costs
Although drug prices are at the forefront of many voters’ minds, they are not actually the main reason the U.S. [...]
A Little More Spending Is Not the End of the World
Investigating the drivers of healthcare spending is the underlying goal of Going Below The Surface. An article published last month in [...]
RAND Report On Health Costs Raises Employer Ire
According to a new RAND study, the Centers for Medicare and Medicaid Services (CMS) are getting the sweetest deal on [...]
Benefits–Not Just Costs–of Medicines Must Be a Part of Discussion
According to Dr. Robert W. Dubois, Interim President and CEO of NPC, in the context of healthcare costs, the amount [...]
Free Strategic Playbook Aims to Bring Cures to Patients More Efficiently
Harvard Business School’s Kraft Precision Medicine Accelerator announced the launch of a playbook specifically developed to bring vital assistance to [...]
Unsupported Price Hikes: Drug manufacturers will be penalized in NASHP’s new model bill
The National Academy for State Health Policy’s (NASHP) newly introduced model law, an Act to Protect Consumers from Unsupported Price Increases [...]
Viewpoint in JAMA: Integrating Personalized Medicine with Population Health Management: The Path Forward
In this viewpoint article published in the Journal of the American Medical Association, the authors posit that genome-wide DNA sequencing [...]
Removing Bias from HEOR: Standardizing the Costs of Adverse Events
By Jim Davis What are the total costs of prescribing a particular drug? At its core, all health [...]
The Affordable Care Act: Perfect? Hardly.
By Debra Gordon I did a radio interview last week with KZYX public radio in Mendocino, CA. The [...]
